Research advances in pharmacogenomics of warfarin

Abstract

Abstract: Warfarin is widely used as one of the coumarins anticoagulation drugs in the clinical.Every physician has been disturbed by its narrow therapic index and bleeding complications.It is a difficult thing for the doctor to use it rationally.However, recently, with the rapid development of molecule biology, some research find that gene polymorphism of pharmacodynamics and pharmacokinetics cause the individual variability in drug response.In this review,we focus on the latest development in pharmacogenomics of warfarin at home and abroad in order to give some suggestions for the individual use of warfarin.

Key words: warfarin, pharmacogenomics, gene polymorphism

CLC Number:

R969
R966

YANG Jian, MIAO Li-yan. Research advances in pharmacogenomics of warfarin[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(12): 1326-1331.

References

1 许俊堂, 胡大一.华法林的临床应用[J].中国医刊, 2004;39:43-6
2 陈晓晖, 赵树进, 袁进.CYP2C9 基因多态性与药物代谢及疾病关系研究进展[J].药物流行病学杂志, 2005;14:178-80
3 Kamali F, Khan TI, King BP, Frearson R, Kesteven P,Wood P,et al.Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin[J].Clin Pharmacol Ther,2004;75:204-12
4Siguret V, Gouin I, Golmard JL, Geoffroy S, Andreux JP, Pautas E.Cytochrome P450 2C9 polymorphisms (CYP2C9) and warfarin maintenance dose in elderly patients[J].Revue de Medecine Interne, 2004;25:271-4
5Aithal GP, Day CP, Kesteven PJL, Daly AK.Association of polymorphisms in the cytochrome P450 CYP2C9 with dose requirement and risk of bleeding complications[J].Lancet, 1999;353:717-9
6 Sanderson S, Emery J, Higgins J.CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients:A HuGEnet(tm) systematic review and meta-analysis[J].GenetMed, 2005;7:98-104
7 Margaglione M, Colaizzo D, D' Andrea G, Brancaccio V, Ciampa A,Grandone E.Genetic modulation of oral anticoagulation with warfarin[J].Thromb Haemost, 2000;84:775-8
8 HigashiMK, Veenstra DL, Kondo LM,Wittkowsky AK, Srinouanprachanh SL, Farin FM, et al.Association between CYP2C9 genetic variations anticoagulation-related outcomes during warfarin therapy[J].JAMA, 2002;287:1691-8
9 Hermida J, Zarza J, Alberca I, Montes R, Lopez ML, Molina E,et al.Differential effects of 2C9＊3 and 2C9＊2 variants of cytochrome P450 CYP2C9 on sensitivity to acenocoumarol [J].Blood, 2002;99:4237-9
10 Taube J, Halsall D, Baglin T.Influence of cytochrome P450 CYP2C9 polymorphisms on warfarin sensitivity and risk of overanticoagulation in patients on long-term treatment[J].Blood,2000;96:1816-9
11 HillmanMA,Wilke RA, CaldwellMD, Berg RL, Glurich I, Burmester JK.Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype[J].Pharmacogenetics, 2004;14:539-47
12 Linder MW, Looney S, Adams JE, Johnson N, Antonino-Green D, Lacefield N, et al.Warfarin Dose Adjustments Based on CYP2C9 Genetic Polymorphisms[J].J Thromb Thrombolysis,2002;14:227-32
13 Joffe HV, Xu R, Johnson FB, Longtine J, Kucher N, Goldhaber SZ.Warfarin dosing and cytochrome P450 2C9 polymorphisms[J].Thromb Haemost, 2004;91:1123-8
14 Zhao F, Loke C, Rankin SC, Guo JY, Lee HS, Wu TS, et al.Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose[J].Clin Pharmacol Ther,2004;76:210-9
15 马量, 余国伟, 叶丁生, 徐鹤云, 邬志勇, 姚航平.细胞色素P4502C9-Leu359 基因变异与华法林抗凝治疗研究[J].心脑血管病防治, 2001;1:21-3
16 李奇林, 谷天祥.CYP2C9 基因的多态性对30 名汉族心脏病患者华法林稳定维持量的影响[D].沈阳:中国医科大学, 2004
17 Leung AY, Chow HC, Kwong YL, Lie AK, Fung AT, Chow WH, et al.Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients[J].Blood, 2001;98:2584-7
18 Freeman BD, Zehnbauer BA, McGrath S, Borecki I, Buchman TG.Cytochrome P450 polymorphisms are associated with reduced warfarin dose[J].Surgery, 2000;128:281-5
19 WadeliusM, Sorlin K,Wallerman O, Karlsson J, Yue QY, Magnusson PK, et al.Warfarin sensitivity related to CYP2C9,CYP3A5, ABCB1 (MDR1) and other factors[J].Pharmacogenomics J, 2004;4:40-8
20 Kragh-Hansen U, Brennan SO, Galliano M, Sugita O.Binding of warfarin, salicylate, and diazepam to genetic variants of human serum albumin with known mutations[J].Mol Pharmacol, 1990;37:238-42
21 Vestberg K, Galliano M, Minchiotti L, Kragh-Hansen U.Highaffinity binding of warfarin, salicylate and diazepam to natural mutants of human serum albumin modified in the C-terminal end[J].Biochem Pharma, 1992;44:1515-21
22 Watanabe H, Kragh-Hansen U, Tanase S, Nakajou K, Mitarai M, Iwao Y, et al.Conformational stability and warfarin-binding properties of human serum albumin studied by recombinant mutants[J].Biochem J, 2001;357;269-74
23 周宏灏.遗传药理学[M].第1 版.北京:科学出版社,2001:269-70
24 Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hortnagel K,Pelz HJ, et al.Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2[J].Nature,2004;427;537-41
25 Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW.Identification of the gene for vitamin K epoxide reductase[J].Nature, 2004;427:541-4
26 Sconce EA, Khan TI,Wynne HA, Avery P, Monkhouse L, King BP, et al.The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements:proposal for a new dosing regimen[J].Blood, 2005;106:2329-33
27 Obayashi K, Nakamura K, Kawana J, Ogata H, Hanada K,Kurabayashi M.VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients[J].Clin Pharmacol Ther, 2006;80:169-78
28 Wadelius M, Chen LY, Downes K, Ghori J, Hunt S, Eriksson N,et al.Common VKORC1 and GGCX polymorphisms associated with warfarin dose[J].Pharmacogenomics J, 2005;5:262-70
29 D' Andrea G, D' Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, et al.A polymorphism in the VKORC1 gene is associated with an interindividual variability in the doseanticoagulant effect of warfarin[J].Blood, 2005;105:645-9
30 Bodin L, Verstuyft C, Tregouet DA, Robert A, Dubert L, Funck-Brentano C, et al.Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity[J].Blood, 2005;106:135-40
31 Yuan HY, Chen JJ, LeeMT,Wung JC, Chen YF, Charng MJ, et al.A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity[J].Hum Mol Genet, 2005;14:1745-51
32 Veenstra DL, You JH, Rieder MJ, Farin FM, Wilkerson HW,Blough DK, et al.Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population[J].Pharmacogenet Genomics,2005;15:687-91
33 Geisen C,Watzka M, Sittinger K, SteffensM, Daugela L, Seifried E, et al.VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation[J].Thromb Haemost, 2005;94:773-9
34 Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS,McLeod H, et al.Effect of VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Dose[J].N Engl J Med, 2005;352:2285-93
35 Lee SC, Ng SS, Oldenburg J, Chong PY, Rost S, Guo JY, et al.Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population[J].Clin Pharmacol Ther, 2006;79:197-205
36 Montes R, Ruiz de Gaona E, Martinez-Gonzalez MA, Alberca I,Hermida J.The c.-1639G >A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients[J].Br J Haematol, 2006;133:183-7
37 SchalekamPT, Brasse BP, Roijers JF, Chahid Y, van Geest-DaalderoPJH, de Vries-Goldschmeding H, et al.VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status:interaction between both genotypes affects overanticoagulation[J].Clin Pharmacol Ther, 2006;80:13-22 Chin J Clin Pharmacol Ther 2006 Dec;11(12)
38 Reitsma PH, van der Heijden JF, Groot AP, Rosendaal FR,Buller HR.A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk[J].PLoS Med,2005;2:e312
39 Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie MD, Scordo MG, et al.Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra-and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans[J].Pharmacogenet Genomics, 2006;16:101-10
40 Aquilante CL, Langaee TY, Lopez LM, Yarandi HN, Tromberg JS,MOhuczy D, et al.Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements[J].Clin Pharmacol Ther, 2006;79:291-302
41 Loebstein R, Vecsler M, Kurnik D, Austerweil N, Gak E, Halkin H, et al.Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9[J].Clin Pharmacol Ther, 2005;77:365-72
42 Rost S, Fregin A, Koch D, CompesM, Muller CR, Oldenburg J.Compound heterozygous mutations in the gamma-glutamyl carboxylase gene cause combined deficiency of all vitamin K-dependent blood coagulation factors[J].Br J Haematol, 2004;126:546-9
43 Kohnke H, Sorlin K,Granath G,WadeliusM.Warfarin dose related to apolipoprotein E (APOE ) genotype[J].Clin Pharmacol J, 2005;61:381-8
44 Kohnke H, Scordo MG, Pengo V, Padrini R,WadeliusM.Apolipoprotein E (APOE) and warfarin dosing in an Italian population[J].Clin Pharmacol J, 2005;61:781-3

[1]	LI Kun, LI Lulu, LI Nannan, HU Weihong, ZHOU Jianchao. Effects of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 767-774.
[2]	LI Qinghua, ZHAO Yan, ZHAO Haigang, GAO Pengfei, XU Bingxin. Value of ABCB1 G2677T gene polymorphism detection in lipid-lowering therapy with atorvastatin in patients suffered from ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 633-640.
[3]	ZHU Li, WEI Bing, LIAO Shi'e, ZHANG Chao, ZHENG Xiaoyu, LIU Yajun. Effects of single nucleotide polymorphism of drug metabolizing enzyme cytochrome P450 on the efficacy of inhaled cortisol hormone in asthmatic children [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 536-543.
[4]	LIU Xiumei, GUO Qianqian, FANG Yuan, CHEN Nan, QI Qi. Pharmaceutical care of patients with antithrombotic therapy after transjugular intrahepatic portal shunt [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 556-560.
[5]	ZHANG Zhiying, JIN Xiuhong, ZHANG Xiaoning, ZHANG Xiangfeng, LUO Qinglin, ZHANG Songlin. Clinical study of TBX21 and ADCY9 polymorphisms in the develop- ment of childhood asthma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 407-412.
[6]	FU Hong, TIAN Lei. Individualized precision therapy for patients with ischemic stroke and hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 870-876.
[7]	CHEN Wengang, YIN Qin, ZHANG Weiwei, ZHOU Lulu, KOU Wanqing, YUAN Xiaolong. Distributions of MTHFR gene polymorphism and its correlation with blood Hcy in patients with hypertension in southern Anhui province [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 768-774.
[8]	WU Yuanzhu, LIU Jun, YANG Kui, PENG Jing, LUAN Jiajie, WEI Jun, ZHANG Dafa, SONG Shuai, YUAN Xiaolong, WANG Zhongfang, ZHANG Nianbao, XIE Dan, JIANG Peng, FAN Jie. Distribution of CYP2C9*3 and VKORC1-1639G>A gene polymorphism in Anhui Han population and their influence on the stable dose of warfarin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 652-659.
[9]	LIAN Jinfang, LIU Yiwei, LIN Cuihong, HUANG Pinfang, LIN Rongfang. Comparison of prediction accuracy between warfarin PPK/PD model and multiple regression dose models [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 267-273.
[10]	SUN Yuanyuan, DENG Kunhong, WANG Siyi, KUANG Yun, ZOU Chan, GUO Chengxian, HE Qingnan, LIU Helin, YANG Guoping. Design and implementation of electronic identity application for gene-directed personalized medicine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 274-280.
[11]	ZHANG Jinhua, LIU Maobai, CAI Mingzhi, ZHENG Yingli, LAO Haiyan, XIANG Qian, DU Liping, ZHU Zhu, DONG Jing, ZUO Xiaocong, LI Xingang, SHANG Dewei, CHEN Bing, YE Yanrong, WANG Yuzhu, GAO Jianjun, ZHANG Jian, CHEN Wansheng, XIE Haitang, JIAO Zheng. Model informed precision dosing of warfarin: China expert consensus report (2022 version) [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1201-1212.
[12]	WEN Dusu, WANG Yi, SUN Jianjun. Comparison of Bayesian method and multiple linear regression method in predicting warfarin dose model [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 33-38.
[13]	WANG Chunling, ZHOU Renjing, FENG Rui, WU Yanneng. Effect of adiponectin 45 T/G gene polymorphism on type 2 diabetes treated with liraglutide [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 312-317.
[14]	XING Kai, GONG Jinyu, LUO Jianquan. Advances on pharmacogenomics of diuretics-related adverse reactions [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 204-212.
[15]	LI Jing, Ma Lijuan, YUAN Yuan, WANG Jie, YU Changzhi, ZHAO Jun. Relationship between gene polymorphism of inhaled glucocorticosteroids budesonide and efficacy in asthma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1250-1258.